

# MAHEC Bamlanivimab Infusion Program

MAHEC has received a supply of the new experimental COVID-19 monoclonal antibody treatment, bamlanivimab (BAM).

This treatment may lessen the severity of illness in high risk, mild to moderately ill people infected with COVID-19 and reduce hospitalizations.

[MAHEC.net/BAM](https://MAHEC.net/BAM)

## Patient treatment criteria:

Bamlanivimab is a treatment option for people with **documented COVID-19 infection** who meet the following criteria:

# High Risk Patients as Defined by Fact Sheet For Healthcare Providers\*\*

Patients with one of the following	Patients ≥55 years of age with one of the following	Patients 12 – 17 years of age with one of the following:
<ul style="list-style-type: none"> <li>• Body mass index (BMI ≥ 35)</li> <li>• Chronic kidney disease (CKD)</li> <li>• Diabetes (DM)</li> <li>• Immunosuppressive disease</li> <li>• Currently receiving immunosuppressive treatment</li> <li>• ≥ 65 years of age</li> </ul>	<ul style="list-style-type: none"> <li>• Cardiovascular disease</li> <li>• Hypertension</li> <li>• Chronic obstructive pulmonary disease/other chronic respiratory disease</li> </ul>	<ul style="list-style-type: none"> <li>• BMI ≥ 85th percentile for their age and gender based on CDC growth charts, <a href="https://www.cdc.gov/growthcharts/clinical-charts.htm">https://www.cdc.gov/growthcharts/clinical-charts.htm</a>, OR sickle cell disease, OR</li> <li>• Congenital or acquired heart disease, OR</li> <li>• Neurodevelopmental disorders, for example, cerebral palsy, OR</li> <li>• Medical related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR</li> <li>• Asthma, reactive airway or other chronic respiratory disease that requires daily medication for control</li> </ul>

## Referrals to the MAHEC BAM infusion program:

- Patients must be referred for treatment by a healthcare provider.
- MAHEC will only be able to administer bamlanivimab to patients 18yo+; you must be in first 10d of symptoms at time of treatment.
- Internal referrals can be made by sending a patient message to **FM Acute Care Infusion**.
- External referrals can be made by **calling 828-589-9750** and completing the attached form (will be loaded on MAHEC website).

[MAHEC.net/BAM](https://www.mahec.net/BAM)

## When calling about a referral please have the following information:

1. Patient's full name (please spell out)
2. Date of birth
3. Date of positive COVID test and symptoms
4. Documentation of COVID-19 PCR test required (fax form to: 828-407-2218)
5. Documentation of patient eligibility for treatment (fax form: 828-407-2218)

[MAHEC.net/BAM](https://www.mahec.net/BAM)

## For More Information:

- Phone calls will be returned within 24 hours Monday through Friday. Weekend calls be returned Monday morning.
- Infusions will take place on the MAHEC Biltmore campus Monday through Friday.
- All patients will be contacted by phone the day of or the day prior to infusion AND the day after infusion.
- All patients will be encouraged to see their primary care provider by telehealth within 3-7 days of the infusion treatment. Patients who do not have a primary care provider will be referred to MAHEC IM for a follow up visit by telehealth.

Questions or concerns, Call Dr. Stephanie Call at 804-347-5322

[MAHEC.net/BAM](https://www.mahec.net/BAM)

Information about Bamlanivimab can be reviewed in the following fact sheets:

- PHE fact sheet for healthcare providers - [Fact Sheet for Health Care Providers: Emergency Use Authorization \(EUA\) of Bamlanivimab \(fda.gov\)](#)
- PHE fact sheet for patients and caregivers - [Fact Sheet for Patients, Parents and Caregivers: Emergency Use Authorization \(EUA\) of Bamlanivimab for Coronavirus Disease 2019 \(COVID-19\) \(fda.gov\)](#)

MAHEC.net/BAM